Last reviewed · How we verify
ICP-723
At a glance
| Generic name | ICP-723 |
|---|---|
| Sponsor | Beijing InnoCare Pharma Tech Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Study of ICP-723 in Patients With Advanced Solid Tumors or Primary Central Nervous System Tumors (PHASE1, PHASE2)
- A Phase I/II Clinical Trial of ICP-723 in the Treatment of Advanced Solid Tumors (PHASE1, PHASE2)
- Evaluate the Safety, Tolerability, and Pharmacokinetics of ICP-723 in Patients With Advanced Solid Tumors (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ICP-723 CI brief — competitive landscape report
- ICP-723 updates RSS · CI watch RSS
- Beijing InnoCare Pharma Tech Co., Ltd. portfolio CI